NASDAQ:VRCA

Verrica Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy VRCA

*Your capital is at risk

$5.87

+0.0800 (+1.38%)

At Close: Jun 03, 2026

Verrica Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 99.99. In total, the insiders bought 119.72M and sold 908.63K VRCA shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	99.99
● Buy	119.72M shares
● Sell	908.63K shares
96% Buy Activity Negligible or No Correlation
Buy Signal High Confidence Jun 01, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 99.99. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (96% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
Nov 26, 2024 Sell	Common Stock G-Gift	Manning Paul B	Director	450 000 Value: $0
Nov 26, 2024 Buy	Common Stock G-Gift	Stalfort John A Iii Director	Director	50 000 Value: $55.5K
Nov 26, 2024 Buy	Common Stock G-Gift	Rieger Jayson CEO And President	CEO / President	50 000 Value: $55.5K
Nov 22, 2024 Buy	Series B Warrants (right to buy)	Caligan Partners Lp See Remarks	Other	421 346 Value: $5.62M
Nov 22, 2024 Buy	Common Stock P-Purchase	Rieger Jayson CEO And President	CEO / President	280 898 Value: $250.0K
Nov 22, 2024 Buy	Series A Warrants (right to buy) P-Purchase	Rieger Jayson CEO And President	CEO / President	140 449 Value: $150.0K
Nov 22, 2024 Buy	Series B Warrants (right to buy) P-Purchase	Rieger Jayson CEO And President	CEO / President	140 449 Value: $187.5K
Nov 22, 2024 Buy	Common Stock P-Purchase	Stalfort John A Iii Director	Director	1 123 595 Value: $1,000.0K
Nov 22, 2024 Buy	Series B Warrants (right to buy) P-Purchase	Stalfort John A Iii Director	Director	561 797 Value: $750.0K
Nov 22, 2024 Buy	Series A Warrants (right to buy) P-Purchase	Stalfort John A Iii Director	Director	561 797 Value: $600.0K
Nov 22, 2024 Buy	Common Stock P-Purchase	Manning Paul B	Director	18 426 966 Value: $16.4M
Nov 22, 2024 Buy	Series A Warrants (right to buy) P-Purchase	Manning Paul B	Director	9 213 483 Value: $9.84M
Nov 22, 2024 Buy	Series B Warrants (right to buy) P-Purchase	Manning Paul B	Director	9 213 483 Value: $12.3M
Nov 22, 2024 Buy	Common Stock P-Purchase	Manning Paul B	Director	4 494 382 Value: $4.00M
Nov 22, 2024 Buy	Series B Warrants (right to buy) P-Purchase	Manning Paul B	Director	2 247 191 Value: $3.00M
Nov 22, 2024 Buy	Series A Warrants (right to buy) P-Purchase	Manning Paul B	Director	2 247 191 Value: $2.40M
Nov 22, 2024 Buy	Series A Warrants (right to buy) P-Purchase	Manning Paul B	Director	2 247 191 Value: $2.40M
Nov 22, 2024 Buy	Series B Warrants (right to buy) P-Purchase	Manning Paul B	Director	2 247 191 Value: $3.00M
Nov 22, 2024 Buy	Common Stock P-Purchase	Manning Paul B	Director	4 494 382 Value: $4.00M
Nov 22, 2024 Buy	Series B Warrants (right to buy) P-Purchase	Manning Paul B	Director	9 213 483 Value: $12.3M
Nov 22, 2024 Buy	Series A Warrants (right to buy) P-Purchase	Manning Paul B	Director	9 213 483 Value: $9.84M
Nov 22, 2024 Buy	Common Stock P-Purchase	Manning Paul B	Director	18 426 966 Value: $16.4M
Nov 22, 2024 Buy	Series A Warrants (right to buy) P-Purchase	Stalfort John A Iii Director	Director	561 797 Value: $600.0K
Nov 22, 2024 Buy	Series B Warrants (right to buy) P-Purchase	Stalfort John A Iii Director	Director	561 797 Value: $750.0K
Nov 22, 2024 Buy	Common Stock P-Purchase	Stalfort John A Iii Director	Director	1 123 595 Value: $1,000.0K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT VERRICA PHARMACEUTICALS INC

Verrica Pharmaceuticals Inc., a dermatology therapeutics company, develops and commercializes treatments for people with skin diseases in the United States. The company's lead product candidate includes VP-102 for the treatment of molluscum contagiosum; that has completed Phase II clinical trial for the treatment of external genital warts; and which is in Phase II clinical trial for treating common warts. It is also developing cantharidin-based p...

Read Full Profile Here